Hepatitis C virus resistance to antiviral therapy

Hepatology

Volumn 32, Issue 5, 2000, Pages 889-896

  Pawlotsky, Jean Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ETHNOLOGY; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0033760016     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.19150     Document Type: Article

References (130)

1. The interferons. Mechanisms of action and clinical applications
2. Biochemistry of interferons and their actions
3. Mechanisms of action of interferon: Potential role in hepatitis C
4. Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its cDNA
5. The human interferon alpha/beta receptor: Characterization and molecular cloning
6. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2 regulators of cell growth and the interferon system
7. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-β and IFN-inducible genes
8. Interferon induction of gene expression through the Jak-Stat pathway
9. Interferon-induced antiviral actions and their regulations
10. Interferon-induced and double-stranded RNA-activated enzymes: A specific protein kinase and 2',5'-oligoadenylate synthetases
11. Expression cloning of a 2-5A-dependent RNase: A uniquely regulated mediator of interferon action
12. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C
13. Mechanisms of antiviral action of interferon
14. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus
15. The MxA protein levels in whole blood lysates of patients with various viral infections
16. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon
17. Mechanism of interferon action: Identification of an RNA binding domain within the N-terminal region of the RNA-dependent P1/eIF-2 protein kinase
18. Translational control in mammalian cells
19. PKR: A new name and new roles
20. The role of the dsRNA-activated protein kinase, PKR, in signal transduction
21. Action of cytokines on the immune response and viral interactions: An overview
22. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine
23. Induction of circulating IL-1 receptor antagonist by IFN treatment
24. Biologic basis for interleukin-1 in disease
25. Type I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells
26. Interferon-α stimulates production of interleukin-10 in activated CD4+ T cells and monocytes
27. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells
28. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C
29. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
30. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
31. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
32. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
33. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
34. Synergystic antiviral activity of interferon-α2b and ribavirin against a surrogate virus of hepatitis C
35. Hepatitis C virus (HCV) dynamics during induction therapy with interferon (IFN) alpha and/or ribavirin
36. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
37. Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C
38. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
39. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
40. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
41. Genotypic analysis of hepatitis C virus in American patients
42. Factors affecting treatment responses to interferon-α in chronic hepatitis C
43. Hepatitis C virus type 1b (II) infection in France and Italy
44. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C
45. 10-Year follow-up after interferon-α therapy for chronic hepatitis C
46. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
47. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron-A) for the treatment of chronic hepatitis C
48. Evaluation of the safety and efficacy of once-weekly PEG/Interferon alfa-2a (Pegasys) for chronic hepatitis C. A multinational, randomized study
49. Dose-dependent acute clearance of hepatitis C virus genotype 1 virus with interferon alfa
50. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
51. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
52. Hepatitis C virus kinetics in chronically infected patients treated with pegylated interferon-alfa
53. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis
54. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
55. The impact of race on response to antiviral therapy in patients with chronic hepatitis C
56. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C
57. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management
58. 'Breakthrough' during recombinant interferon therapy for chronic hepatitis C. Evaluation of associated pretreatment factors and evolution of HCV replication and genetic complexity
59. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C
60. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis
61. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN
62. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon
63. The alcoholic patient with hepatitis C virus infection
64. Hepatitis C and alcohol
65. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers
66. Factors predictive of a beneficial response to therapy of hepatitis C
67. Management of hepatitis C
68. Consensus Statement
69. Treatment of chronic hepatitis C in special groups
70. Hepatitis C and HIV infection: Biological, clinical, and therapeutic implications
71. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection
72. New treatment strategies in non-responder patients with chronic hepatitis C
73. Treatment of patients with chronic hepatitis C and normal ALT levels
74. Should the patients with histologically mild chronic hepatitis C be treated?
75. Alpha-2a interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels
76. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis
77. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
78. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
79. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
80. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection
81. Retreatment with interferon-alpha of chronic hepatitis C virus infection
82. Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data
83. Quasispecies nature of hepatitis C virus and response to alpha interferon: Significance as a predictor of direct response to interferon
84. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
85. Variability of hepatitis C virus
86. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region
87. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
88. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
89. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
90. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
91. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
92. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
93. The 'interferon sensitivity determining region' of hepatitis C virus is a stable sequence element
94. A suggested extension of the HCV ISDR does not alter our former conclusions on its predictive value for IFN response
95. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
96. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection
97. Long-term response to interferon alpha is unrelated to 'interferon sensitivity determining region' variability in patients with chronic hepatitis C virus-1b infection
98. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes
99. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
100. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication
101. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
102. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
103. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
104. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
105. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
106. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance
107. HCV NS5A (1b) mutants show different phosphorylation patterns, inhibit interferon (IFN) antiviral activity, but do not affect PKR and cell proliferation status
108. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response
109. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
110. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
111. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
112. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
113. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
114. Long-term genetic evolution of the non-structural protein 5A (NS5A) of hepatitis C virus (HCV) in patients treated with interferon (IFN)-alpha and IFN-ribavirin combination
115. Density heterogeneities of hepatitis C virus in human sera due to the binding of β-lipoproteins and immunoglobulins
116. The non structural (NS) 5A protein of hepatitis C virus
117. Internal ribosome entry site within hepatitis C virus RNA
118. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism
119. Evolution of chronic non-A, non-B hepatitis after α-interferon therapy: Evidence for a rebound phenomenon
120. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
121. Hepatitis C virus replication during acute infection in the chimpanzee
122. Quantitation of hepatitis C virus RNA in liver transplant recipients
123. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection
124. The role of immune responses in the pathogenesis of hepatitis C virus infection
125. Hepatitis C virus infection: Virus/host interactions
126. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
127. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
128. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy
129. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
130. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis